Healthcare use is elevated two decades before a first demyelinating event and differs by age and sex
Open Access
- 29 January 2025
- journal article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (2) , 415-432
Abstract
Objective: Elevated healthcare use before multiple sclerosis (MS) onset suggests earlier opportunity to identify MS. Yet their timing and sociodemographic effects are unclear. We examined rates of healthcare use (and by age/sex) for >two decades pre‐MS onset.Methods: We identified people with MS (PwMS) using administrative data from Canada (Ontario) and Sweden (1991–2020) (“administrative” cohort), and the Swedish MS Registry (“clinical” cohort). The first MS/demyelinating diagnostic code (administrative) or symptom onset (clinical) defined MS onset. We compared annual rates of healthcare use (hospital, physician, and emergency‐room [ED]) pre‐onset between PwMS and up to five matched population controls using negative binomial regression, and by age/sex.Results: The administrative cohort = 35,018/136,007 PwMS/controls (Ontario), and 10,269/51,297 (Sweden). Rates of healthcare use were higher for PwMS than controls up to 28 (of 29) years (Ontario) and up to 15 (of 19) years (Sweden) pre‐onset. Annual healthcare use rose steadily as onset approached, particularly escalating 7 years pre‐onset in Ontario (e.g., hospital visit rate ratios [RRs] exceeded 1.30), and 6 years in Sweden (physician visit RRs > 1.10). RRs peaked the year pre‐onset (ED visits [Ontario] = 3.04; 95% CI: 2.94–3.13, physician visits [Sweden] = 2.51; 95% CI: 2.44–2.59). In the year pre‐onset, RRs were disproportionately higher for males (ED RRs [Ontario] = 3.30; 95% CI: 3.13–3.48 vs. females = 2.90; 95% CI: 2.79–3.02), and dropped steadily by age (physician visit RRs [Sweden] = 2.61/2.27/1.97/1.72 for 50/40/30/20‐year‐olds). The smaller clinical cohort (7604/37,974 PwMS/controls) exhibited similar patterns, albeit more modest, with RRs elevated up to 5 years pre‐onset (physician visit RR [year‐5] = 1.08; 95% CI: 1.02–1.14; RR [year‐1] = 1.39;1.33–1.46).Interpretation: Higher healthcare use was evident decades before MS onset, escalating 6–7 years pre‐onset, peaking the year before, being disproportionately higher for males and older PwMS.Keywords
Funding Information
- National Multiple Sclerosis Society (RG5063A4/1/RFA‐2103‐37392)
- MS Canada (EGID:P002/903124)
This publication has 38 references indexed in Scilit:
- Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated SyndromeJAMA Neurology, 2023
- Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated SyndromeAnnals of Neurology, 2022
- How to improve access to medical imaging in low- and middle-income countries ?eClinicalMedicine, 2021
- Gestational vitamin D and offspring risk of multiple sclerosis: a systematic review and meta-analysisAnnals of Epidemiology, 2020
- Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple SclerosisJAMA Neurology, 2020
- Update of the MDS research criteria for prodromal Parkinson's diseaseMovement Disorders, 2019
- Prodromal symptoms of multiple sclerosis in primary careAnnals of Neurology, 2018
- Factors associated with onset, relapses or progression in multiple sclerosis: A systematic reviewNeuroToxicology, 2017
- MDS research criteria for prodromal Parkinson's diseaseMovement Disorders, 2015
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisCochrane Database of Systematic Reviews, 2015